FDA Approves New Treatment for Uncomplicated Urinary Tract Infections
Retrieved on:
Wednesday, April 24, 2024
Urine, UTI, FDA, Public, Patient, Staphylococcus, Urinary tract infection, Pivmecillinam, Priority review, Safety, Woman, Cosmetics, Food, Dietary supplement, Heated tobacco product, Infection, Research, Human services, Bacteria, Nausea, Staphylococcus saprophyticus, Escherichia coli, Porphyria, Vaccine, History, Female, Therapy, System, Tablet, Diarrhea, Hypersensitivity, Multimedia, Animal, Proteus mirabilis, Clinical trial, Metabolic disorder, Division, Ibuprofen
SILVER SPRING, Md., April 24, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
Key Points:
- SILVER SPRING, Md., April 24, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.
- "The FDA is committed to fostering new antibiotic availability when they prove to be safe and effective, and Pivya will provide an additional treatment option for uncomplicated UTIs."
- Uncomplicated UTIs are bacterial infections of the bladder in females with no structural abnormalities of their urinary tract.
- Approximately one-half of all women experience at least one UTI in their lifetime.